PAR04-122 Extramural Research Facilities Construction C*

描述(由申请人提供)： 耶希瓦大学阿尔伯特·爱因斯坦医学院已经开始建设遗传和转化医学价格中心(CGTM)，并寻求NIH/NCRR的支持，以完成CGTM 5楼26,509平方英尺的无人居住外壳空间。这一层将是新的传染病研究所(IID)的所在地，该研究所由实验室和共享资源组成，负责处理新出现的疾病和生物战的风险。现场化学基因组学设施将促进基于基因的方法在药物开发中的应用. IID建设计划将通过提供以下内容实现6个主要目标： 1)实验室，使用无毒分枝杆菌作为运送载体，用于免疫其他病原体； 2)生物安全3级设施，包括用于雾化结核分枝杆菌(结核分枝杆菌)和其他需要遏制的病原体的动物实验区； 3)研究针对强毒结核分枝杆菌和炭疽芽孢杆菌的单抗保护机制的实验室， 4)实验室研究黑色素在新生隐球菌毒力中的致病机制和作用； 5)高通量的化学基因组学设施，用于使用新的酶途径进行药物发现；以及 6)在涉及微生物遗传学和宿主反应基因的实验上合作的生物信息学专业知识。 将几个优秀的传染病研究人员小组整合到更大和更改进的设施中，将提供协同扩展的机会，增进对微生物发病机制的了解，并促进新疗法的开发。这些目标与美国尚未解决的关键健康问题直接相关。

DESCRIPTION (provided by applicant): Albert Einstein College of Medicine of Yeshiva University has begun construction of the Price Center for Genetic and Translational Medicine (CGTM) and seeks NIH/NCRR support for completion of 26,509 gross square feet of uninhabited shell space on the CGTM 5th floor. This floor will house the new Institute of Infectious Diseases (IID) comprising laboratories and shared resources and addressing risks of emerging disease and biological warfare. The application'of gene-based approaches to drug development will be fostered by an on-site chemical genomics facility. The IID construction plan will achieve 6 major objectives by providing: 1) Laboratories for experiments using avirulent mycobacteria as a delivery vector for immunization against other pathogens; 2) A Biosafety Level 3 facility including an area for animal experiments on aerosolized Mycobacterium tuberculosis (M.tb), and other pathogens requiring such containment; 3) Laboratories to study the mechanism of monoclonal antibody protection for treatment or protection against virulent M.tb and Bacillus anthracis, 4) Laboratories to study the pathogenesis and role of melanin in the virulence of Cryptococcus neoformans; 5) A high throughput chemical genomics facility for drug discovery using novel enzymatic pathways; and 6) Bioinformatics expertise to collaborate on experiments involving the genetics of microorganisms and host response genes. The consolidation of several outstanding groups of infectious disease investigators into larger and improved facilities will offer opportunity for synergistic expansion and advance understanding of microbial pathogenesis and spur the development of novel therapies. These goals are directly relevant to critical, unresolved health issues in the United States.